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Objectives: To determine the biological characteristics of oropharyngeal squamous cell carcinoma (OpSCC) and
related outcome.
Design: Retrospective study.
Methods: Patients (N=60) with primary OpSCC from 2000 to 2005 were retrospectively identified from Pathology
database and the outcome was confirmed through chart review. Among these, 41 biopsy samples with enough
tissues were retrieved to construct a tissue microarray for detection of the presence of high-risk human
papillomavirus (HPV) using Chromogenic in situ hybridization (CISH) as well as the expression of p16 and cyclin D1
using immunohistochemistry.
Main outcome measures: Disease-free survival.
Results: Among 60 patients, 39 (65%) patients had no recurrence or died without disease at the last follow-up
(disease-free survival or Group 1), and 21 (35%) patients had persistent disease or died of disease (progression-free
survival or Group 2). Although follow-up time was twice as long in group 1 (4.7 ± 2.2 vs. 2.0 ± 1.6 years; P < 0.0001),
there was no difference between the 2 groups in age, gender, smoking/alcohol habits, TNM staging and treatment
modalities. Among those 41 cases with available tumour tissues, there was no difference in HPV status and p16
expression between the 2 groups but a significant difference in cyclin D1 expression (P = 0.05). Using Kaplan-Meir
survival analysis and log-rank test, cyclin D1 overexpression was highly associated with a poor prognosis when
comparing time to outcome (P < 0.0001).
Conclusion: Cyclin D1 overexpression is a potential prognostic marker of OpSCC.
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free survival, PrognosisThe incidence of oropharyngeal squamous cell carci-
noma (OpSCC), particularly those arising in the base of
the tongue and in the tonsillar region, rises every year
between 1973 and 2004 [1]. This increasing trend occurs
despite the decrease in the incidence of oral cavity, la-
ryngeal and hypopharyngeal cancers as well as the de-
creased prevalence in smoking, which is a primary risk
factor for these cancers [2]. Molecular studies have iden-
tified human papillomavirus (HPV) as a causative agent
in 60% to 80% of patients with OpSCC [3]. HPV-16 ac-
counts for a large majority of HPV-positive OpSCC (80-* Correspondence: CPoh@bccancer.bc.ca
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reproduction in any medium, provided the or90%) compared to other oncogenic types such as HPV-
18, 31 or 33 [4,5].
HPV-positive OpSCCs have distinct risk factors and
molecular profiles. These tumours are thought to be as-
sociated with certain types of sexual behavior, but not to
tobacco smoking or alcohol use. On a molecular level,
almost all HPV-positive tumours express wild-type p53
tumour suppressor genes. Expression of HPV viral E6
and E7 oncoproteins inactivates p53 and the retinoblast-
oma protein pRb. p16 protein expression is subsequently
elevated due to loss of the pRb negative feedback loop
[6]. p16 then inhibits cyclinD1-CDK4/6 (cyclin-
dependent kinase 4/6) complexes, which are important
regulators for the cell cycle to progress from the G1
phase to the S phase. As a result, HPV-positive cancers. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lin D1 expression [7,8]. In other head and neck cancers
that are not typically related to HPV, cyclin D1 over-
expression has been linked with poor outcome, particu-
larly in hypopharyngeal cancers [9]. However there is
not a large amount of evidence suggesting its prognostic
significance in oropharyngeal cancer.
Given the worldwide growing epidemic of HPV-
associated oropharyngeal cancers, characterization of
HPV-associated molecular markers is becoming increas-
ingly important for determining their impact on the
prognosis of disease and for guiding the development of
new therapeutic interventions. The objective of our
study was to determine the association of cyclin D1 and
HPV status in OpSCC and its relevance on patient out-
come. Since cyclin D1 overexpression has been asso-
ciated with a poor prognosis in cancers of other head
and neck regions, we hypothesize it is associated with a
poor prognosis in oropharyngeal cancer.
Methods
Patient and tumour tissue
This is a retrospective case series. The study has
obtained approval from the Research Ethics Board at the
University of British Columbia and has been in com-
pliance with research conduct guidelines at this institu-
tion. A total of 60 patients (n = 60) with primary
OpSCC from the year 2000 to 2005 were retrospectively
identified from the Vancouver General Hospital Pa-
thology database. This duration was chosen so that all
patients have had at least 5 years of follow-up after their
initial treatment. These patients were confirmed to have
no previous history of cancer and their outcome infor-
mation were collected through electronic chart review
from the patient information database at the British
Columbia Cancer Agency (BCCA). Demographic and
clinical data were also collected from chart review, in-
cluding age, gender, smoking status, alcohol intake,
treatment received, follow-up time and survival status.
Tumour staging using the TNM classification [10] was de-
termined by review of clinical notes, radiology reports,
surgical notes and pathology reports. Among the included
patients, 41 (68%) formalin-fixed biopsy specimens with
enough tissues were retrieved from the pathology archive
for the construction of tissue microarrays.
Tissue microarray (TMA) construction
Tissue microarray was constructed as previously described
[11]. The most representative areas of tumours were
chosen by the pathologist (CFP). Tissue cores of 0.6 mm
in diameter from these representative areas of formalin-
fixed paraffin-embedded (FFPE) tumour blocks were taken
by a manual tissue arrayer (Beecher Instrument, SI, USA).
The cores were then transferred in duplicates to therecipient TMA block. The recipient blocks were then se-
rially cut into 4 μm tissue sections for chromogenic in situ
hybridization and immunohistochemistry.
Chromogenic in situ Hybridization (CISH) for HPV
high-risk subtypes and HPV-16/18
High-risk HPV subtypes and specifically HPV subtypes 16
as well as 18 in FFPE TMA sections were detected by
using chromogenic in situ hybridization (CISH). Two
HPV probes were examined in this study: HPV-HR (cock-
tail for high-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68, DAKO, Denmark), and HPV-16/18
(DAKO, Denmark). In brief, each of the tissue sections
were deparaffinized, rehydrated and pretreated with target
retrieval solution (DAKO) for 20–40 minutes at 97°C.
After antigen retrieval with Proteinase K (Sigma-Aldrich,
Canada) and blocking, the slides were hybridized with a
biotinylated HPV-HR probe and HPV-16/18-specific
probe. After initial binding of streptavidin horseradish per-
oxidase complex to the probe, signal amplification was
performed using biotinyl tyramide. Positive hybridization
signals were visualized by adding the chromogenic sub-
strate diaminobenzidine (DAB). SiHa and SCC-9 cell lines
were used as a positive and negative control, respectively.
Slides were scored positive for HPV if a nuclear, punctuate
pattern of signals was observed in > 60% of the tumour
nuclei, which was indicative of integrated HPV DNA into
the host genome. The scoring was performed by the same
pathologist (CFP).
Immunohistochemistry (IHC) for p16 and cyclin D1
IHC was performed on TMA tissue sections that were
deparaffinized. After target retrieval, sections were incu-
bated with primary antibodies for p16 (Roche mtm la-
boratories AG, Heidelberg, Germany) [12] and cyclin D1
(Cell Signaling, Ontario, Canada) [13] with duration and
temperature specified for each marker (Table 1). The
sections were then incubated with the EnVision+ System
(DAKO Corporation) for cyclin D1 for detection of
antigen-antibody reactions. Sections were visualized with
DAB and counterstained with Mayer’s hematoxylin. The
staining intensity was scored as a percentage of stained
tumour cells (0% - 100%). Tumour cells with a greater
than or equal to 50% staining percentage were scored as
“positive”. Otherwise they were scored as “negative”. The
scoring was again performed by the same pathologist
(CFP).
Statistical analysis
All statistical analyses were performed using SPSS/
PASW Statistics (version 19, SPSS Inc., Chicago, IL).
The Fisher’s exact test was used to compare dichoto-
mous (e.g., gender, alcohol consumption and N staging)
or other categorical (e.g., smoking status, T staging,
Table 1 Antibodies used in immunohistochemistry for p16 and cyclin D1











SiHa Muscle CINtecW Histology Kit (Roche mtm laboratories AG,
Heidelberg, Germany)
Cyclin D1 1:35 4°C, Overnight Nuclear SCC-9 Muscle Cyclin D1 (92G2) Rabbit mAb #2978 (Cell Signaling,
Ontario, CA)
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was used to compare parametric variable (e.g., age and
follow-up time). Disease-free survival was estimated
using the Kaplan-Meier method with log-rank test for
determining statistical significance. Disease-free survival
was defined as time from the day of cancer diagnosis to
the date of death from OpSCC or to the date of last
follow-up. Multivariate analysis was not performed given
the small sample size of the study. A P value of 0.05 or
less was considered statistically significant.
Results
Patient population
Seventy-seven patients were initially identified to have pri-
mary oropharyngeal squamous cell carcinoma from the
year 2000 to 2005 from the Pathology database of the
Vancouver General Hospital. Seventeen patients were ex-
cluded from the study after reviewing the electronic charts
at the BC Cancer Agency. Reasons of exclusion included
(1) primary tumours not at oropharyngeal site (n = 10);
(2) no definitive treatment received due to patient refusal
or palliation (n = 6); and (3) loss of follow-up (n = 1). A
total number of 60 patients were included for the final
analysis. The patient characteristics are shown in Table 2.
The mean follow-up time was 4 ± 2.4 years. The patients
were categorized into two outcome groups based on dis-
ease (OpSCC) status after treatment: Group 1 represented
disease-free survival; Group 2 represented progression-
free survival or disease-specific deaths. Among the 60 pa-
tients, 39 (65%) had no recurrence or died without disease
(Group 1) and 21 (35%) had persistent disease or died of
disease (Group 2). There was no significant difference
among patient characteristics including age, smoking, al-
cohol intake, and TNM staging between the two outcome
groups (Table 2). Follow-up time was significantly longer
for Group 1 compared to Group 2 (4.7 ± 2.2 years vs.
2.0 ± 1.6 years; P < 0.0001).
HPV status and p16 expression
Of the 60 patients included in the study, 41 had sufficient
tumour tissues for analysis. Among these, 56% (n= 23)
tested positive for high risk HPV DNA (HPV-HR) and
66% (n = 27) showed p16 overexpression. All cases that
were HPV-HR-positive were also p16-positive (see exam-
ples in Figure 1). None of the tumours were HPV-positive
and p16-negative. Approximately 9.8% of tumours werefound to be HPV-negative and p16-positive. The sensitiv-
ity, specificity, positive predictive value and negative pre-
dictive value using p16 for the presence of HPV-HR DNA
defined by CISH approach were 0.85, 1.0, 1.0, and 0.78, re-
spectively. Among those cases that were positive for HPV-
HR (n = 23), 68% were positive for HPV-16/18 DNA.
While 7 out of 7 tumours from non-smokers were positive
for p16, interestingly 20 out of 32 tumours from smokers
(62.5%) were also positive for p16 (P = 0.08).
There was no difference in HPV status and p16 ex-
pression between Groups 1 and 2 (Table 3). However,
disease-free survival was improved in tumours that were
positive for HPV-HR (P =0.05, Figure 2A) compared to
tumours that were positive for HPV-16/18 (P =0.38,
Figures 2B). Although it was not statistically significant,
the p16-positive group showed better disease-free sur-
vival than the p16-negative group (P = 0.08; Figure 2C).
Cyclin D1 expression and disease-free survival
Twelve tumours were cyclin D1-positive (12/41, 29%)
and twenty-nine tumours were cyclin D1-negative (29/
41, 71%). Among the cyclin D1-negative tumours, 21
(78%) were positive for p16, a currently accepted surro-
gate marker for the presence of HPV DNA. For those
tumours that were cyclin D1-positive (n = 14), only 43%
(n = 6) were positive for p16. Using Fisher’s exact test,
there was no difference in cyclin D1 expression between
the two outcome groups (Table 3). However, the im-
proved disease-free survival over time was significant in
the cyclin D1-negative group using the log-rank analysis
(P < 0.0001, hazard ratio 18.0, 95% confidence interval
4.37 to 74.03; Figure 2D).
Discussion
Cyclin D1 overexpression has been reported in squa-
mous cell carcinoma in a variety of head and neck sub-
sites including the larynx, hypopharynx and tongue
[9,14,15]. Its prognostic significance in OpSCC has been
contradictory [16-22]. Our study has demonstrated cyc-
lin D1 overexpression is associated with a poor prog-
nosis in primary OpSCC. Cyclin D1 is a well-known
oncogene in a variety of human cancers. It is a key regu-
lator of cell proliferation. It promotes cell cycle progres-
sion through G1 phase by forming complexes with
CDK4 and CDK6, which in turn phosphorylate the re-
tinoblastoma protein pRb [23]. This causes pRb to
Table 2 Comparison of patient characteristics between two outcome groups
Total (N = 60) Group 1a (N=39, 65%) Group 2a (N = 21, 35%) P value
Mean age at diagnosis (yr ± SD) 60.4 ± 11.7 59.8 ± 11.3 61.4 ± 12.6 0.63
Gender
Male 46 (77) 30 (77) 16 (76)
Female 14 (23) 9 (23) 5 (24) 1
Smoking Habit
Non-smokers 14 (23) 10 (26) 4 (19) 0.78
Former smokers (quit > 5 yr) 15 (25) 9 (23) 6 (29)
Current smokers 29 (48) 20 (51) 9 (43)
Unknowne 2 (3) 0 (0) 2 (10)
Alcoholb
Never or light 51 (85) 34 (87) 17 (81) 1
Heavy 7 (12) 5 (13) 2 (10)
Unknowne 2 (3) 0 (0) 2 (10)
T staging
1 25 (42) 19 (49) 6 (29) 0.44
2 15 (25) 9 (23) 6 (29)
3 12 (20) 6 (15) 6 (29)
4 3 (5) 2 (5) 1 (5)
Unknowne 5 (8) 3 (8) 2 (10)
N staging
N0 7 (12) 6 (15) 1 (5) 0.4
N+ 51 (85) 32 (82) 19 (90)
Unknowne 2 (3) 1 (3) 1 (5)
TNM stagingc
1 2 (3) 2 (5) 0 (0) 0.61
2 4 (7) 3 (8) 1 (5)
3 11 (18) 6 (15) 5 (24)
4 41 (68) 27 (69) 14 (67)
Unknowne 2 (3) 1 (3) 1 (5)
Treatment information
Surgery (S/T) only 3 (5) 2 (5) 1 (5) 0.12
Radiation (XRT) onlyd 30 (50) 18 (46) 12 (57)
Chemotherapy only 11 (18) 5 (13) 6 (29)
Combined S/T and XRT 16 (27) 14 (36) 2 (10)
Mean Follow-Up Time (yr ± SD) 4 ± 2.4 4.7 ± 2.2 2 ± 1.6 < 0.0001
aOutcome: Group 1, those survived with no disease or died due to other cause (disease-free survival); Group 2, those alive with disease or died of disease
(progress-free survival or disease-specific deaths).
bHeavy alcohol intake was defined as > 3 drinks/day for males and > 2 drinks/day for females.
cTNM staging is based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed 2010.
dRadiation only include radiation only with/without induction chemotherapy.
eMissing values (Group 1 (N): Group 2 (N)): Smoking Habit (0:2), Alcohol (0:2), T-staging (3:2); Nodal Status (1:1); TNM staging (1:1).
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genes essential for cell cycle progression from G1 phase
to S phase, during which cells proliferate [24]. It has
been suggested that cyclin D1 plays a role in the late
phase of tumour progression given its correlation withlymph node metastases, histological aggressiveness and
poor prognosis [9].
Cyclin D1 overexpression was higher in patients with
adverse outcomes in our study, but the difference was
not statistically significant. With the log-rank analysis,
Figure 1 Examples of a case from Group 1 (favourable outcome group; upper panel, A, B, C) and a case from Group 2 (adverse
outcome group; lower panel, D, E, F). A (diffuse punctate signals) and D (negative) showing CISH staining of HPV-HR DNA; B (diffuse strong
cytoplasmic staining and nuclear staining) and E (negative) showing IHC staining of p16 protein; C (negative) and F (diffuse strong nuclear
staining) showing IHC staining of cyclin D1. (Original magnification 100×).
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was statistically significant between the cyclin D1-
positive and cyclin D1-negative groups. Although this
study had a small sample size, we fitted a multivariate
Cox Proportional Hazard model to examine the poten-
tial joint and interaction effects among markers (data
not shown). The analysis showed that cyclin D1 over-
expression was the only and independent variable de-
monstrating significance in predicting poor outcome in
disease-free survival. Despite the small number of pa-
tients in our study, our finding strongly suggest thatTable 3 Comparison of tumour HPV DNA, p16 and cyclin D1 s
Total (N=60) Group 1 (N=3
HPV-HR
Positive 23 (56) 14 (61)
Negative 18 (44) 9 (39)
HPV-16/18
Positive 15 (37) 8 (35)
Negative 26 (63) 15 (65)
p16
Positive 27 (66) 16 (70)
Negative 14 (34) 7 (30)
Cyclin D1
Positive 12 (29) 4 (17)
Negative 29 (71) 19 (83)cyclin D1 could potentially be a useful prognostic
marker for OpSCC.
In our study, HPV DNA was detected in 56% of
OpSCC with the entire 56% being p16-positive. This is
consistent with the reported numbers from previous
studies [25,26]. 9.8% of tumours were p16-positive and
HPV-negative, which has also been reported in the li-
terature [26]. Overall, our study supports p16 as an ef-
fective surrogate marker for high-risk HPV infection
with high sensitivity and specificity (85% and 100%, re-
spectively). Cyclin D1 expression should be down-tatus between outcome groups 1 and 2









Figure 2 Kaplan Meier analysis for disease-free survival and log-rank test for comparison between groups: A, HPV-HR (P =0.05);
B, HPV-16/18 (P = 0.38); C, p16 (P = 0.08); and D, cyclin D1 (P < 0.0001).
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cell carcinoma as a result of pRb suppression [7,24]. In
our study, 78% (N=21) of cyclin D1-negative tumours
were associated with p16 overexpression. This inverse
relationship is consistent with the hypothesis that HPV
positivity and subsequent p16 upregulation leads to sup-
pression of cyclin D1 expression.
Our study has not found any significant association
between smoking or alcohol intake and tumour HPV
status. Interestingly, all the nonsmokers showed p16/
HPV positivity but 62.5% of smokers have also shown
p16/HPV positivity. This may argue against the current
literature observation that HPV-positive tumours tend
to occur in non-smokers and non-drinkers [27].
One of the limitations of this study is that it was a
retrospective review, thus it relied on the accuracy of
written or dictated medical records. A second limitation
is the small sample size. We were only able to identify a
total number of 60 cases of primary oropharyngeal car-
cinoma with known outcome from 2000 to 2005. Thus
we may not have enough patients in order to detect a
statistical significance in the expression of markers be-
tween the two outcome groups. We were also not able
to perform a multivariate analysis due to the small sam-
ple size. The next step of this project is to widen our
search through the BC Cancer Registry in order to iden-
tify more primary oropharyngeal cancer cases and to
retrieve their tumour tissues for tissue microarray con-
struction. A prospective arm of the study is alsounderway to recruit patients with new oropharyngeal
carcinoma diagnosis to participate in our investigation.
Conclusion
Our preliminary results have demonstrated cyclin D1
overexpression is a potential prognostic marker of pri-
mary oropharyngeal squamous cell carcinoma. Further
understanding of these genetic alterations leading to ma-
lignant progression is critical to future secondary pre-
vention strategies and therapeutic interventions for
patients with HPV-positive oropharyngeal squamous cell
carcinoma.
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